TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hemoglobin SS, Hemoglobin Sß0thal or Hemoglobin SC documented by prior hemoglobin electrophoresis.~2. Age 9 years or greater, age 22 years or less; pediatric age range, old enough to comply with mask and give reliable pain assessment score.~3. Acute pain crisis defined as pain in abdomen, back and/or extremities that cannot be explained by a diagnosis other than sickle cell disease.~4. Initial pain score at least 6 cm; to optimize the likelihood of observing a significant difference in change in pain score between INO treated and placebo groups. Based on data from our previous study, it is anticipated that patients will have an average pre-inhalation pain score of approximately 8 cm.~Exclusion Criteria:~1. \> 24 pain crises in the last 12 months. Patients with very frequent pain crisis may have biologic and/or psychosocial pathophysiology that differs from those with fewer pain crises.~2. Pain crisis treated at a medical facility within the last 12 hours.~3. Use of investigational drugs other than hydroxyurea within the last 30 days.~4. Significant respiratory compromise (initial SaO2 \< 90%) and/or patients likely to have acute chest syndrome (chest pain and infiltrate) will be eliminated.~5. Clinically significant acute or chronic cardiac dysfunction.~6. Acute priapism.~7. New focal neurologic symptoms.~8. Concurrent documented or suspected bacterial or parvovirus infection.~9. Temperature \> 38.4ºC. These patients may have concomitant infection.~10. Transfusion within 30 days or chronic transfusion therapy.~11. Pregnant female~12. Cigarette smoker \> 1/2 ppd.~13. Allergy to morphine~    -

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): inhaled NO
- 2 (Type: PLACEBO_COMPARATOR): room air inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven carcinoma of the pancreas that is locally advanced~* ECOG performance status 0- 2~* Adequate labs~* No prior abdominal radiation therapy~* No other concurrent clinically evident malignancy, except inactive nonmelanoma skin cancer, inactive cervical cancer, or other cancer for which the patient has been disease-free for 5 years~* All disease must be encompassed within a radiotherapy portal~* Not pregnant or nursing~Exclusion Criteria:~* Patient has metastatic disease on radiological staging~* systemic therapy.~* Patient has known active infection with HIV, hepatitis C or hepatitis B~* Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug.~* Patient is deemed to be have obvious resectable disease at presentation~* Received any investigational agent within a month prior to enrollment.~* Neuroendocrine tumors of the pancreas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemzar/Abraxane and Radiation Therapy (Type: EXPERIMENTAL): Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Local Injection Under US Control in GTPS.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients complaining of lateral hip pain for more than 1 month.~2. NRS lateral hip pain score ≥ 4 in the preceding week.~3. Failure of another standard treatment:~   * Physiotherapy: local therapy or a stretching program, or~  * Analgesic treatment (minimum of 5 days of consecutive therapy, including, but not limited to, NSAIDs).~4. Typical lateral hip pain reproduced by palpation of the greater trochanter~Exclusion Criteria:~1. Age younger than 18 years old~2. Concomitant local surgical intervention for tumours, infection or fracture, based on clinical history and physical examination~3. Previous ipsilateral prosthetic hip surgery~4. Scheduled ipsilateral hip surgery within 3 months~5. Fibromyalgia (diagnosis established by a rheumatologist)~6. Flair of chronic inflammatory joint disease (as defined by a rheumatologist)~7. Skin lesions at the injection site~8. Allergy to one of the studied drugs~9. Anticoagulation with internal normalized ration (INR) \>3~10. Blood coagulation disorder, such as haemophilia.~11. Serious and uncontrolled psychiatric disease (as assessed by the clinician as a contraindication for steroid)~12. Other contraindications to steroid use, such as:~    * uncontrolled diabetes (non-fasting blood glucose \> 10 mmol/L)~   * unstable hypertension (systolic pressure \> 160mmHg or diastolic pressure \> 100mmHg), or~   * open or closed angle glaucoma.~13. Requirement for systemic steroids (including steroid injections) or dose modification of disease modifying anti-rheumatic drugs during the preceding three months. Oral corticosteroids (\< 10mg / day of Prednisone or equivalent) will be permitted providing that the dose has been stable for 4 weeks prior to inclusion and that the patient is expected to remain on the baseline dose for the duration of the study.~14. Presence of a pacemaker or other metallic object that constitutes a CI to MRI, or severe claustrophobia~15. Pregnant women (according to a pregnancy test) or nursing (breastfeeding) mothers.~16. Unwillingness or inability to give informed consent.~17. Unavailability for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rapidocain and bethametsaone (Type: ACTIVE_COMPARATOR): Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)
- sterile saline (Type: PLACEBO_COMPARATOR): Placebo arm with 5ml of sterile saline (NaCl) solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* preterm premature rupture of membranes~* 26 - 32.6 weeks gestation~* cervical dilation \</= 4 cm~Exclusion Criteria:~* suspected intrauterine or intraamniotic infection~* \> 6 hours of tocolysis prior to admission~* positive fetal lung maturity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Magnesium sulfate (Type: ACTIVE_COMPARATOR): x 48 hours IV
- Normal saline (Type: PLACEBO_COMPARATOR): x 48 hours IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NIRS as a Continuous Noninvasive Monitoring System of Liver/Kidney Graft Perfusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All pediatric patients admitted to our ICU for postoperative care after liver/kidney transplantation~Exclusion Criteria:~* Obesity (BMI \> 35)~* Presence of a surgical plate over the graft~* Impossibility of probe positioning, because of surgical wound, medication or drainage~* Bilirubin level \> 30 mg/dL

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Near-InfraRed Spectroscopy (NIRS) (Type: None): The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: G-PUR® for Reduced Dietary Fumonisin Bioavailability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female subjects~2. Age 18-55 years~3. BMI 17-27~4. Subjects are in good clinical and mental health as established by medical history and physical examination~5. Subject understands the scope of the study and agrees to strictly adhere to the study related diet plan~6. Written informed consent~Exclusion Criteria:~1. Pregnancy or breastfeeding.~2. Lack of willingness or capacity to co-operate appropriately~3. Regular use of medications in the previous 2 months (except oral contraception)~4. History of malignancies within the past two years or on current anticancer treatment~5. History of gastrointestinal pathology such as clinically relevant gastritis, gastric ulcers, inflammatory bowel disease, chronic constipation~6. History of diarrhoea within the past 14 days of screening~7. History of gastrointestinal surgery with exception of appendectomy~8. History of any chronic liver disease~9. History of autoimmune disease requiring treatment within the past two months of screening~10. Known symptomatic food allergies~11. Active infection (including HIV and hepatitis B or C), or abnormalities in laboratory testing, vital signs, or physical examination~12. Hypersensitivity to aluminium and/or silicon~13. Chronic renal disease requiring dialysis~14. Alcohol, cigarette or drug abuse~15. Presence of any condition that impacts compliance with the study procedures~16. Use of any investigational or non-registered product (drug or device) within 30 days preceding the first study product administration, or planned use during the study period~17. Employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to the sponsor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 2.0g G-PUR® oral - Placebo (Type: EXPERIMENTAL): None
- Placebo - 2.0g G-PUR® oral (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or above~* Diagnosed with CRC and prescribed with either XELOX for FOLFOX4 chemotherapy treatment~Exclusion Criteria:~* Patients less than 18 years of age~* Persons related unequally to investigators~* Patients who are mentally/cognitively disabled~* Patients who refuse to give consent to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX4 (Type: None): Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
- XELOX (Type: None): Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* · All the patients requiring an endoscopy within the framework of a colorectal cancer~  * All the patients requiring a low digestive endoscopy within the framework of the diagnosis or of the follow-up of a colorectal cancer, realized in the CHU of Nice.~ * Realization of a preliminary medical examination~ * Obligation for all the patients to be affiliated to the Social Security~ * Signature of the informed consent~Exclusion Criteria:~* • Pushed acute severe of the disease defined by the score of Truelove and Witss or the score of Lichtiger \> 10 (cf appendix)~  * severe endoscopic Hurts returning the practice of dangerous additional biopsies~ * Disorders of the coagulation or the patient under anti-vitamin K, aspirin or clopidogrel.~ * Patient presenting an unchecked renal, respiratory, hepatic or cardiac insufficiency~ * Patient known positive HIV~ * vulnerable People: pregnant or breast-feeding women (a pregnancy test will be realized), minors, adults under guardianship or guardianships, deprived of freedom

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- biopsy (Type: OTHER): We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~* healthy patients;~* patients with colonic Crohn disease in acute phase;~* patients with colonic Crohn disease in chronic phase;~* patients with ulcerative colitis in acute phase;~* patients with ulcerative colitis in chronic phase;~* patients with colon cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults of at least 18 years of age, but not older than 80 years~2. Due to undergo elective major amputation of the lower extremity (above the knee amputation (AKA), below the knee amputation (BKA), total knee amputation (TKA), transmetatarsal amputation (TMA), toe amputation) from all causes.~Exclusion Criteria:~1. Pregnancy~2. Increased intracranial pressure or intraocular pressure~3. Allergy to ketamine~4. Morbid obesity (BMI \> 40 kg/m2)~5. Significant comorbidity (ASA physical status classification \> 3)~6. Inability to communicate with the investigators~7. Any history of known or suspected drug or alcohol abuse~8. History of impaired liver function~9. Significant history of hallucinations, delusions or other psychiatric medical condition the investigator feels will prevent assessment of adverse events of study drug.~10. Significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression.~11. Exposure to cytochrome P450 3A4 inhibitors or inducers (including grapefruit products) within 2 weeks before enrollment; the inability to avoid these products during ketamine administration.~12. Poorly-controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral Ketamine (Type: EXPERIMENTAL): Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Conversion From Fast Acting Oral Opioids to Abstral®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained.~* 18 years or older, of both genders.~* Opioid tolerant patients~* Estimated frequency of BTcP 0.5-4 times a day.~Exclusion Criteria:~* Treatment with SL fentanyl within two weeks prior to screening.~* Recent or planned therapy that would alter pain or responses to analgesics.~* Treatment with monoamine oxidase inhibitor \< 14 days before or concurrent with SL fentanyl treatment.~* Significantly reduced liver and/or kidney function.~* Significant prior history of substance abuse.~* Pregnancy, breast feeding or woman of childbearing potential not using adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SL Fentanyl conversion (Type: EXPERIMENTAL): * Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~* Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Outcomes in the Placement of Boomerang Percutaneous Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient that has a percutaneous Boomerang closure device placed after having a neuro-intervention~Exclusion Criteria:~* Patients that do not have this medical device used post procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Boomerang percutaneous closure unit (Type: None): patients having a Boomerang percutaneous closure device after a Neurointerventional study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following:~  * Patient at City of Hope or Kaiser hospital who underwent prior autologous or allogeneic matched-related hematopoietic stem cell transplantation (HSCT) or matched-unrelated HSCT for treatment of hematological malignancies, including aplastic anemia or myelodysplastic syndromes~    * Must agree to return to City of Hope for screening every 2-4 weeks during the flu season~   * 100-365 days post-transplant~   * Any prior therapy allowed~ * Employee volunteer from the City of Hope who agrees to have a nasopharyngeal wash performed at General Clinical Research Center every 2 weeks during the flu season~* Must be eligible (per physicians instructions) and vaccinated during the 2008-2009 or 2009-2010 flu season~PATIENT CHARACTERISTICS:~* Life expectancy \> 9 months~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Early Nasal Polyposis With Topical Triamcinolone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients with early nasal polyposis~Exclusion Criteria:~* Age \< 18 years~* Patients with active sinus infections~* Patients on long term steroids~* Allergy or sensitivity to steroids~* Patients with Antrochoanal polyps~* Patients who received topical steroids by bio-resorbable sponge or oral steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triamcinolone (Type: EXPERIMENTAL): Triamcinolone soaked nasopore dressing
- Control Group (Type: PLACEBO_COMPARATOR): Saline soaked sponge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility